134 related articles for article (PubMed ID: 17234019)
21. Plant stanol esters are potentially cost-effective in the prevention of coronary heart disease in men: Bayesian modelling approach.
Martikainen JA; Ottelin AM; Kiviniemi V; Gylling H
Eur J Cardiovasc Prev Rehabil; 2007 Apr; 14(2):265-72. PubMed ID: 17446806
[TBL] [Abstract][Full Text] [Related]
22. The impact of prevention on reducing the burden of cardiovascular disease.
Kahn R; Robertson RM; Smith R; Eddy D
Circulation; 2008 Jul; 118(5):576-85. PubMed ID: 18606915
[TBL] [Abstract][Full Text] [Related]
23. Cost-effectiveness model of use of genetic testing as an aid in assessing the likely benefit of aspirin therapy for primary prevention of cardiovascular disease.
Shiffman D; Slawsky K; Fusfeld L; Devlin JJ; Goss TF
Clin Ther; 2012 Jun; 34(6):1387-94. PubMed ID: 22560621
[TBL] [Abstract][Full Text] [Related]
24. Economic analysis of treatments reducing coronary heart disease mortality in England and Wales, 2000-2010.
Fidan D; Unal B; Critchley J; Capewell S
QJM; 2007 May; 100(5):277-89. PubMed ID: 17449875
[TBL] [Abstract][Full Text] [Related]
25. Cost-effectiveness of raising HDL cholesterol by adding prolonged-release nicotinic acid to statin therapy in the secondary prevention setting: a French perspective.
Roze S; Ferrières J; Bruckert E; Van Ganse E; Chapman MJ; Liens D; Renaudin C
Int J Clin Pract; 2007 Nov; 61(11):1805-11. PubMed ID: 17850322
[TBL] [Abstract][Full Text] [Related]
26. Cost-effective primary care-based strategies to improve smoking cessation: more value for money.
Salize HJ; Merkel S; Reinhard I; Twardella D; Mann K; Brenner H
Arch Intern Med; 2009 Feb; 169(3):230-5; discussion 235-6. PubMed ID: 19204212
[TBL] [Abstract][Full Text] [Related]
27. Cost-effectiveness analysis between primary and secondary preventive strategies for gastric cancer.
Lee YC; Lin JT; Wu HM; Liu TY; Yen MF; Chiu HM; Wang HP; Wu MS; Hsiu-Hsi Chen T
Cancer Epidemiol Biomarkers Prev; 2007 May; 16(5):875-85. PubMed ID: 17507609
[TBL] [Abstract][Full Text] [Related]
28. Varenicline as compared to bupropion in smoking-cessation therapy--cost-utility results for Sweden 2003.
Bolin K; Mörk AC; Willers S; Lindgren B
Respir Med; 2008 May; 102(5):699-710. PubMed ID: 18289839
[TBL] [Abstract][Full Text] [Related]
29. [The best of epidemiology and cardiovascular prevention in 2006].
Thomas D; Collet JP; Cottin Y; Cournot M; Ducimetière P; Ferrières J; Paillard F; Valensi P; Zeller M; Cambou JP
Arch Mal Coeur Vaiss; 2007 Jan; 100 Spec No 1():57-64. PubMed ID: 17405566
[TBL] [Abstract][Full Text] [Related]
30. Cost-effectiveness of intensive atorvastatin treatment in high-risk patients compared with usual care in a postgeneric statin market: economic analysis of the Aggressive Lipid-lowering Initiation Abates New Cardiac Events (ALLIANCE) study.
Mullins CD; Rattinger GB; Kuznik A; Koren MJ
Clin Ther; 2008; 30 Pt 2():2204-16. PubMed ID: 19281915
[TBL] [Abstract][Full Text] [Related]
31. Costs, health effects and cost-effectiveness of alcohol and tobacco control strategies in Estonia.
Lai T; Habicht J; Reinap M; Chisholm D; Baltussen R
Health Policy; 2007 Nov; 84(1):75-88. PubMed ID: 17403551
[TBL] [Abstract][Full Text] [Related]
32. An economic analysis of aspirin desensitization in aspirin-exacerbated respiratory disease.
Shaker M; Lobb A; Jenkins P; O'Rourke D; Takemoto SK; Sheth S; Burroughs T; Dykewicz MS
J Allergy Clin Immunol; 2008 Jan; 121(1):81-7. PubMed ID: 17716716
[TBL] [Abstract][Full Text] [Related]
33. A model for undertaking effectiveness and cost-effectiveness analyses of primary preventive strategies in cardiovascular disease.
Liew D; Lim SS; Bertram M; McNeil JJ; Vos T
Eur J Cardiovasc Prev Rehabil; 2006 Aug; 13(4):515-22. PubMed ID: 16874139
[TBL] [Abstract][Full Text] [Related]
34. Cost-effectiveness of high-dose atorvastatin compared with regular dose simvastatin.
Lindgren P; Graff J; Olsson AG; Pedersen TJ; Jönsson B;
Eur Heart J; 2007 Jun; 28(12):1448-53. PubMed ID: 17371782
[TBL] [Abstract][Full Text] [Related]
35. Health economic evaluation of controlled and maintained physical exercise in the prevention of cardiovascular and other prosperity diseases.
Annemans L; Lamotte M; Clarys P; Van den Abeele E
Eur J Cardiovasc Prev Rehabil; 2007 Dec; 14(6):815-24. PubMed ID: 18043305
[TBL] [Abstract][Full Text] [Related]
36. Cost effectiveness of community-based physical activity interventions.
Roux L; Pratt M; Tengs TO; Yore MM; Yanagawa TL; Van Den Bos J; Rutt C; Brownson RC; Powell KE; Heath G; Kohl HW; Teutsch S; Cawley J; Lee IM; West L; Buchner DM
Am J Prev Med; 2008 Dec; 35(6):578-88. PubMed ID: 19000846
[TBL] [Abstract][Full Text] [Related]
37. Cost-effectiveness of clopidogrel in myocardial infarction with ST-segment elevation: a European model based on the CLARITY and COMMIT trials.
Berg J; Lindgren P; Spiesser J; Parry D; Jönsson B
Clin Ther; 2007 Jun; 29(6):1184-202. PubMed ID: 17692733
[TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness analysis of a European primary-care physician training in smoking cessation counseling.
Pinget C; Martin E; Wasserfallen JB; Humair JP; Cornuz J
Eur J Cardiovasc Prev Rehabil; 2007 Jun; 14(3):451-5. PubMed ID: 17568248
[TBL] [Abstract][Full Text] [Related]
39. [How to evaluate the cost/effectiveness ratio of different therapies of coronary disease].
Roquebrune JP; L'Héritier P; Gibelin P; Baudouy M; Camous JP; Blanc P; Bossan S; Morand P
Arch Mal Coeur Vaiss; 1992 Feb; 85(2):239-44. PubMed ID: 1348616
[TBL] [Abstract][Full Text] [Related]
40. Cost-effectiveness of the Danish smoking cessation interventions: subgroup analysis based on the Danish Smoking Cessation Database.
Olsen KR; Bilde L; Juhl HH; Kjaer NT; Mosbech H; Evald T; Rasmussen M; Hiladakis H
Eur J Health Econ; 2006 Dec; 7(4):255-64. PubMed ID: 16816946
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
